Trial NCT04805125
Publication Speich B, Clin. Infect. Dis., 2022
Primary outcome on the report: Positive antibody response to SARS-CoV-2 spike (S1) protein receptor binding domain in human serum or plasma assessed by the commercial immunoassay Elecsys Anti-SARS-CoV-2 S (Elecsys S) from Roche Diagnostics. The outcome is binary using a threshold of ≥0.8 units/ml as defined by the manufacturer.

Note: The risk of bias by domain corresponds to the highest risk of bias among outcomes by domain.
The overall risk of bias corresponds to the overall highest risk of bias assessed among outcomes.